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ABSTRACT
Three major guidelines deal with blood pressure thresholds and targets for antihypertensive drug therapy in chronic kidney
disease (CKD) patients: the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the
Management of Blood Pressure in Chronic Kidney Disease; the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; and the
2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. However, a careful reading of the three guidelines
leaves the practicing physician confused about the definition of CKD, how hypertension and secondary hypertension
should be diagnosed in CKD patients and what the blood pressure thresholds, targets and compelling indications of
antihypertensive drug therapy should be for this population. Current guidelines refer to different CKD populations and
propose different definitions of hypertension, different thresholds to initiate antihypertensive therapy in CKD patients and
different BP targets compelling antihypertensive drug use. The different bodies producing guidelines should work together
towards a unified definition of CKD, a unified concept of hypertension and unified BP thresholds and targets for
hypertensive drug therapy for CKD patients. Otherwise they risk promoting confusion and therapeutic nihilism among
physicians and patients.
Keywords: blood pressure targets, blood pressure thresholds, chronic kidney disease, hypertension, renin–angiotensin
system, treatment
INTRODUCTION
Three major guidelines deal with blood pressure (BP) thresholds
and targets for hypertensive drug therapy in chronic kidney
disease (CKD) patients: the 2012 Kidney Disease: Improving
Global Outcomes (KDIGO) Clinical Practice Guideline for the
Management of Blood Pressure in Chronic Kidney Disease;
the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PCNA Guideline for the Prevention, Detection, Evaluation,
and Management of High Blood Pressure in Adults; and the 2018
European Society of Cardiology (ESC)/European Society of
Hypertension (ESH) Guidelines for the Management of Arterial
Hypertension [1–3]. However, a careful reading of the three
guidelines leaves the practicing physician confused about the
definition of CKD, how hypertension and secondary hyperten-
sion should be diagnosed in CKD patients and what the BP
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thresholds and targets for antihypertensive drug therapy
should be for this population. We now discuss the similarities
and differences between these guidelines and call for unified
basic concepts that prevent confusion among patients and
physicians.
WHAT IS CKD?
The current international consensus concept of CKD by the
KDIGO 2012 states that CKD is defined as abnormalities of kid-
ney structure or function, present for >3 months, with implica-
tions for health [4]. Individual criteria, on their own, allow the
diagnosis of CKD. These are a decreased glomerular filtration
rate (GFR) (<60 mL/min/1.73 m2) or evidence of kidney damage
such as albuminuria [albumin excretion rate 30 mg/24 h, uri-
nary albumin:creatinine ratio (UACR) 30 mg/g], urine sediment
abnormalities, electrolyte and other abnormalities due to tubular
disorders, abnormalities detected by histology, structural abnor-
malities detected by imaging or a history of kidney transplanta-
tion. To rephrase, CKD may be diagnosed in patients with normal
renal function, but this requires that they have additional evi-
dence of kidney disease, such as pathological albuminuria.
Although the definition is very precise and was supposed to pro-
vide a unified concept and language, it has often been misinter-
preted [5]. Thus high-quality journals such as the New England
Journal of Medicine use the concept ‘CKD Stage 1 or 2’ to represent
individuals with an estimated GFR (eGFR) >60 mL/min/1.73 m2 in
the absence of any demonstrated evidence of CKD: they apply
the term CKD to individuals without CKD, that is, individuals
who are healthy from the kidney point of view and have normal
renal function [5, 6]. The confusion is further compounded by the
different concepts of CKD embedded in guidelines from special-
ties other than nephrology [7]. However, it is most surprising that
BP guidelines use concepts of CKD different than the consensus
of KDIGO [2, 3] (Figure 1A–C). It would be desirable that they ex-
plicitly refer to the 2012 KDIGO definition and if they do want to
single out specific CKD categories, they should do so throughout
the manuscript and make clear at the start of the CKD section
and throughout to what categories they are referring (CKD G3–G5,
or CKD G3–G5 and/or A3) and not equate ‘CKD’ with just specific
categories within the wider CKD concept [4].
In the 2017 American College of Cardiology (ACC)/American
Heart Association (AHA) Guideline for the Prevention,
Detection, Evaluation, and Management of High Blood Pressure
in Adults, the CKD section does not provide a definition of CKD
when it states that adults with hypertension and CKD should be
treated to a BP goal of <130/80 mmHg and the 2012 KDIGO defi-
nition of CKD is not cited among the references [2]. In agree-
ment with the KDIGO definition, kidney transplant is
considered CKD without any further consideration of albumin-
uria or GFR and it is recommended they be treated like other
CKD patients. However, only a subset of CKD patients, defined
as category G3 or higher or G1 or G2 with A3 albuminuria
(300 mg/day or UACR 300 mg/g) have a compelling indication
for renin–angiotensin system (RAS) blockade. Thus CKD catego-
ries G1 and G2 with albuminuria category A2 (30–299 mg/g) are
not the subjects of any specific antihypertensive drug indica-
tions. Further confusion is created earlier in the guideline, in
section 8.1.2, BP Treatment Threshold and the Use of CVD Risk
Estimation to Guide Drug Treatment of Hypertension: ‘Use of
BP-lowering medication is recommended for primary prevention
of cardiovascular disease (CVD) in adults with no history of CVD
and with an estimated 10-year atherosclerotic cardiovascular dis-
ease (ASCVD) risk 10% and a systolic BP of 130 mmHg or higher
or a diastolic BP of 80 mmHg or higher’. Thus the reader is re-
ferred to an online calculator of the ACC/AHA Pooled Cohort
Equations (http://tools.acc.org/ASCVD-Risk-Estimator/) to esti-
mate the 10-year risk of atherosclerotic CVD. This calculator
allows clinicians to introduce information on the presence of dia-
betes, but as of 5 August 2019, not the presence of CKD. Thus any
risk calculation will not take into account the presence of CKD.
The fact that CKD is missing for the recommended online calcu-
lator is not discussed in the text in section 8.1.2 dealing with risk
estimation. However, a footnote to the treatment algorithm indi-
cates, ‘Note that patients with diabetes mellitus or CKD are auto-
matically placed in the high-risk category’. In any case, what is
understood by ‘CKD’ is not clarified in this footnote.
In the 2018 ESC/ESH Guidelines for the Management of
Arterial Hypertension, CKD is defined as an eGFR <60 mL/min/
1.72 m2 with or without proteinuria in a footnote to Figure 6 of
the text that shows the drug treatment strategy for hyperten-
sion in CKD patients [3]. This is consistent with other references
to CKD in the same text and corresponds to the 2012 KDIGO cat-
egories G3–G5 and thus excludes CKD patients with normal re-
nal function (categories G1/A2, G1/A3, G2/A2 and G2/A3) [3].
Figure 1D provides an approximation of the impact of the differ-
ent CKD definitions on the population that is covered by recom-
mendations provided by guidelines that use different concepts
of CKD. Curiously, at some point, this guideline uses the con-
cept CKD ‘grade’ (e.g. Figure 1 on page 3034 of the document) to
refer to the current 2012 KDIGO concept of category. In other
sections, the term used is stage (e.g. page 3033 of the docu-
ment), which corresponds to the older Kidney Disease
Outcomes Quality Initiative nomenclature. However, only the
KDIGO manuscript is cited in the references. The indiscriminate
and exchangeable use of the terms grade and stage is confusing
when the current KDIGO term is category.
WHAT IS HYPERTENSION?
The two major hypertension guideline bodies provide different
definitions of hypertension, and this is also confusing for
patients, medical students and physicians.
The 2017 ACC/AHA Guideline for the Prevention, Detection,
Evaluation, and Management of High Blood Pressure in Adults
defines hypertension as an office systolic BP 130 or an office
diastolic BP 80 mmHg [2], while for the 2018 ESC/ESH
Guidelines for the Management of Arterial Hypertension, hyper-
tension is an office systolic BP 140 and/or office diastolic BP
90 mmHg [3]. Essentially this means that a patient diagnosed
with hypertension in the USA because of a BP of 135/85 mmHg
would no longer be considered to have hypertension after mov-
ing to Europe. Furthermore, the 2017 ACC/AHA guideline [2] rec-
ognize Stages 1 and 2 hypertension and the 2018 ESC/ESH
guidelines [3] recognize Grades 1, 2 and 3 hypertension, but the
thresholds in mmHg for these diagnoses do not match.
To complicate matters further, the 2018 ESC/ESH guidelines
[3] also provide definitions of hypertension based on daytime
ambulatory, nighttime ambulatory, 24 h ambulatory and home
mean BP (Table 1). For example, for systolic BP, threshold values
for a diagnosis range from 120 to 135 mmHg and for diastolic
BP, from 70 mmHg to 85 mmHg, depending on the method of
BP assessment chosen.
At least both guidelines agree on the equivalence between
office BP and other measurements of BP, although there is no
logical lineal correspondence between the values in the differ-
ent techniques that allow extrapolation of BP values sitting be-
tween those provided (Figure 2).
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WHAT ARE THE BP THRESHOLDS TO INITIATE
HYPERTENSIVE DRUG THERAPY IN CKD
PATIENTS?
There are also major differences between the guidelines regard-
ing BP thresholds to initiate antihypertensive drug therapy and
specifically regarding thresholds for CKD patients (Figure 3).
A major difference relates to the elderly. For the 2017 ACC/AHA
guideline [2], individuals 80 years of age should be treated
when systolic BP is 130 mmHg and/or diastolic BP 80 mmHg,
independent of the presence of CKD, while in the 2018 ESC/ESH
guidelines [3], for individuals 80 years of age the threshold for
initiation of antihypertensive therapy is systolic BP 160 mmHg





FIGURE 1: Different concepts of CKD used in recent hypertension guidelines. (A) CKD categories according to KDIGO 2012 Clinical Practice Guideline for the Evaluation
and Management of Chronic Kidney Disease [4]. A diagnosis of CKD can be made in the presence of a GFR <60 mL/min/1.73 m2 or in the presence of albuminuria
>30 mg/24h (UACR >30 mg/g) or in the presence of other evidence of kidney injury persisting for >3 months. (B) The 2017 ACC/AHA guideline does not clarify the con-
cept of CKD that they are using, and they do not reference the 2012 KDIGO definition of CKD. However, CKD patients have specific BP thresholds and targets, while
patients with patients with CKD G3–G5 or A3 category additionally have a compelling indication for RAS blockade [2]. In drawing the figure, we have assumed that the
2017 ACC/AHA guideline refers to the 2012 KDIGO definition of CKD. (C) The 2018 ESC/ESH guidelines concept of CKD [3]. (D) Percentage of the adult (20–74 years old)
and elderly (75–84 years old) hypertensive German population that fulfils each definition of CKD [8]. The 75- to 84-year-olds are representative of the >80-year-old pop-
ulation cited by the 2018 ESC/ESH guidelines to propose BP thresholds and targets for CKD patients [3]. In this study, hypertension was defined as a systolic BP
140 mmHg, a diastolic BP 90 mmHg or the use of antihypertensive drugs [8].
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In the 2017 ACC/AHA guideline, not all patients with a diag-
nosis of hypertension merit pharmacological therapy. Thus
therapy is restricted to those meeting the European concept of
hypertension (systolic BP 140 mmHg and/or 90 mmHg) or to
those having an American diagnosis of hypertension (systolic
BP 130 mmHg and/or diastolic BP 80 mmHg) that additionally
have either CVD or a 10-year ASCVD risk 10% as per the ACC/
AHA Pooled Cohort Equations [2]. This level of ASCVD risk is
found in patients with diabetes or CKD and in patients 80
years of age. In this regard, the ACC/AHA Pooled Cohort
Equations are validated for US adults ages 45–79 years in the ab-
sence of concurrent statin therapy [2]. The guideline specifically
states that for those 80 years of age, the 10-year ASCVD risk is
generally >10%, and thus the systolic BP threshold for antihy-
pertensive drug treatment for patients >79 years of age is
130 mmHg.
For the 2018 ESC/ESH guidelines, the office BP thresholds for
treatment are grossly equivalent to the thresholds used to diag-
nose hypertension. That is, a diagnosis of hypertension (systolic
BP 140 mmHg and/or diastolic BP 90 mmHg) means that ther-
apy for hypertension should be prescribed when there are no
associated diseases or when the patient has diabetes or CKD [3].
However, there are two exceptions:
a. For patients with coronary artery disease or stroke, treat-
ment may be considered when systolic BP is 130–140 mmHg,
except if they are 80 years of age.
b. For individuals 80 years of age, the threshold to prescribe
treatment is systolic BP 160 and/or diastolic BP 90 mmHg
in all cases, independent of the presence of associated con-
ditions. Basically this means that the therapeutic implica-
tions of a diagnosis of hypertension are different for the
elderly than for younger individuals.
In summary, in the 2018 ESC/ESH guidelines, the diastolic BP
threshold for therapy is always 90 mmHg, but the systolic BP
threshold ranges from 130 to 160 mmHg depending on age
and associated conditions. Focusing on CKD patients, therapy
for hypertension is indicated when systolic BP is 140 mmHg
and/or diastolic BP is 90 mmHg, except for individuals
80 years of age, in whom the systolic BP threshold is
160 mmHg. The thresholds for younger individuals and, above
all, the threshold for those 80 years of age are different from
the 2017 ACC/AHA guideline for CKD patients—systolic BP
130 mmHg and/or diastolic BP 80 mmHg, which are indepen-
dent of age (Figure 3).
The thresholds of both general guidelines also differ from
those of the 2012 KDIGO for CKD patients: systolic BP
140 mmHg and/or diastolic BP 90 mmHg for A1 albuminuria
and systolic BP 130 mmHg and/or diastolic BP 80 mmHg for
albuminuria A2 or A3, independent of GFR (Figure 3) [1].
WHAT ARE THE BP TARGETS FOR CKD
PATIENTS ON HYPERTENSIVE DRUG
THERAPY?
The BP target for both the 2012 KDIGO and 2017 ACC/AHA guide-
lines is to bring BP below the thresholds that trigger prescription
therapy [1, 2] (Figure 3). However, the 2018 ESH/ESC guidelines
differ from this apparently logical approach [3]. It is difficult to
grasp why nephrologists would let the BP of elderly CKD
patients rise to >160/90 mmHg before prescribing antihyperten-
sive medication, but once this is prescribed, they have a target
BP of 130–139/70–79 mmHg, as suggested by the 2018 ESH/ESC
guidelines [3]. And it is even more difficult to understand why
the 2018 ESH/ESC guidelines have a higher threshold to initiate
antihypertensive medication in those >80 years of age, while
this population is, again, because of age, automatically consid-
ered as very high risk by the 2017 ACC/AHA guidelines and thus
the threshold to initiate therapy is lowered to 130/80 mmHg [2].
Additionally, different guidelines use different concepts of
CKD when providing recommendations on compelling indica-
tions for specific antihypertensive drugs. The 2012 KDIGO guide-
line suggests RAS blockade for patients with a UACR 30–300 mg/g
and recommends RAS blockade for a UACR>300 mg/g, indepen-
dent of eGFR values [1]. In contrast, the 2017 ACC/AHA guideline
excludes CKD patients with an eGFR> 60 mL/min/1.73 m2 that
have a UACR of 30–300 mg/g [2] and the 2018 ESC/ESH guidelines
Table 1. BP thresholds to define hypertension, depending on the country where you live or how the BP was measured
Systolic BP (mmHg) Diastolic BP (mmHg) Criterion
140 90 Office BP, 2018 ESC/ESH
135 85 Home BP, daytime ambulatory BP, 2018 ESC/ESH
130 80 24h mean ambulatory BP, 2018 ESC/ESH
Office BP, 2017 ACC/AHA. Equivalent to Home BP, daytime ambulatory BP
125 75 24h mean ambulatory BP equivalent to 2017 ACC/AHA office BP definition of hypertension
120 70 Nighttime ambulatory BP, 2018 ESC/ESH
110 65 Nighttime ambulatory BP equivalent to 2017 ACC/AHA office BP definition of hypertension
Either the systolic or the diastolic BP value is diagnostic of hypertension. The 2018 ESC/ESH guidelines [3] provide a table with non-office definitions, while the 2017
ACC/AHA guideline [2] provides a table with corresponding values of BP for home BP, office BP, and daytime, nighttime and 24 h mean ambulatory BP. The 2018 ESC/
ESH guidelines are shown in blue and the 2017 ACC/AHA guideline is in red.
FIGURE 2: Corresponding values of systolic BP and diastolic BP assessed as office
BP, home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM: daytime,
nighttime and 24 h) [2]. Please note that there is no logical lineal correspondence
and thus it is difficult to extrapolate BP values between those provided. The fig-
ure is not meant to represent thresholds to diagnose hypertension. Systolic BP
values are shown as shades of blue and diastolic BP values as shades of red/
brown.
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exclude those with an eGFR >60 mL/min/1.73 m2 from the com-
pelling indication of RAS blockade for CKD patients [3].
WHAT IS THE METHOD USED TO ASSESS BP
THRESHOLDS AND TARGETS?
While guidelines provide a series of considerations regard-
ing the value of ambulatory and home BP monitoring in cor-
rectly classifying patients into hypertension, white-coat
and masked hypertension, and even the 2018 ESH/ESC
guidelines [3] provide hypertension diagnostic criteria for
these other approaches, the key thresholds for initiating
therapy and BP targets are mainly provided in terms of of-
fice BP.
HOW IS HYPERTENSION SECONDARY TO CKD
DIAGNOSED?
An interesting and, from our point of view, insufficiently
addressed issue is how to differentiate hypertension-induced
kidney injury from hypertension secondary to CKD. By defect,
guidelines appear to attribute any CKD in a hypertensive patient
to hypertension, unless demonstrated otherwise. The 2018 ESH/
ESC guidelines state, ‘The diagnosis of hypertension-induced
renal damage is based on the finding of reduced renal function
and/or the detection of albuminuria’. [3] Thus, apparently for
them, the coexistence of hypertension and decreased eGFR and/
or presence of pathological albuminuria is diagnostic of
hypertension-induced kidney injury rather than setting up a di-
agnostic work-up for kidney disease–induced hypertension.
According to the 2017 ACC/AHA guidelines, a specific, reme-
diable cause of hypertension can be identified in 10% of adult
patients with hypertension [2]. Renal parenchymal disease is
reported to have a prevalence of 1–2%, however, the denomina-
tor (all hypertensive individuals?) for such prevalence is not
clarified. In any case, the prevalence is much lower than for re-
novascular disease, which is reported as 5–34% depending on
the clinical situation (hypertension alone, 5%; hypertension
starting dialysis, 22%; hypertension and peripheral vascular dis-
ease, 28%; hypertension in the elderly with congestive heart
failure, 34%). The low contribution of renal parenchymal disease
to secondary hypertension is surprising, given that 10% of the
adult population has CKD and the prevalence of CKD is >60% of
those >80 years of age [8, 9]. This means that for the immense
majority of patients with both hypertension and CKD, CKD is
not thought to be causing hypertension. The guideline states
that renal parenchymal disease may be suspected by the pres-
ence of urinary tract infections; obstruction, haematuria; uri-
nary frequency and nocturia; analgesic abuse; family history of
polycystic kidney disease; elevated serum creatinine; abnormal
urinalysis; an abdominal mass (polycystic kidney disease) or
skin pallor [2]. Renal ultrasound is considered a screening test.
The 2018 ESH/ESC guidelines suggest that 5–15% of hyper-
tensive patients have secondary hypertension [3]. Surprisingly,
it goes on to list four causes of secondary hypertension that
may be present in 10% of hypertensive patients, potentially
driving the prevalence of secondary hypertension to 45%. It lists
parenchymal kidney disease as a cause in 2–10% of hyperten-
sive patients. This is up to 10-fold higher than the figure in the
2017 ACC/AHA guideline. Renal parenchymal disease is listed as
a key contributor to secondary hypertension at all ages. However,
among those 65 years of age, it is estimated that 5–10% of
FIGURE 3: Different thresholds to initiate antihypertensive drug therapy and therapeutic targets in CKD patients. (A) The 2012 KDIGO Clinical Practice Guideline for the
Management of Blood Pressure in Chronic Kidney Disease [1]. (B) The 2017 ACC/AHA guideline [2]. (C) The 2018 ESC/ESH guidelines [3]. Please note that thresholds and
therapeutic targets differ between guidelines and the curious situation for the discrepant thresholds and therapeutic targets recommended by the 2018 ESC/ESH guide-
lines, especially for the elderly. Please note that the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease and the
2017 ACC/AHA guideline provide no range of target values, so there is no lower limit for the recommended systolic or diastolic BP. Red colouring of the columns repre-
sents above-threshold BP. Blue colour represents within-target BP. Individual numerical values in red represent the highest values of the three guidelines for the same
concept (systolic or diastolic BP), in orange represent intermediate values and in green represent the lowest values of the three guidelines for the same concept. For the
KDIGO and ACC/AHA guidelines, the same values are thresholds and targets. For the ESC-ESH guidelines, thresholds and targets do not match.
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hypertensive patients have one of three causes of hypertension
(atherosclerotic renovascular disease, renal parenchymal disease
and thyroid disease). Thus the prevalence of renal parenchymal
disease as a cause of hypertension in this age group is estimated
at <5–10%, well below the estimated prevalence of CKD in the
general population in this age range. The guideline indicates that
suggestive symptoms and signs of a CKD caudation include dia-
betes, haematuria, proteinuria, nocturia, anaemia or renal mass
in adult polycystic CKD and evaluations include plasma creati-
nine and electrolytes, eGFR, urine dipstick for blood and protein,
UACR and renal ultrasound.
Overall, in our opinion, the contribution of CKD as a driver of
hypertension is not adequately clarified by the guidelines: they
do not agree on the percentage of hypertensive patients who
have hypertension secondary to CKD, and although tests are
listed to uncover parenchymal kidney disease, the criteria to as-
sign CKD as the cause of hypertension are unclear as opposed
to being coexistent conditions or CKD being secondary to hyper-
tension. In this regard, from 27 to 69% of adult hypertensives
have CKD (Figure 1D) [8]. Thus current guidelines suggest that
in the majority of hypertensive patients with CKD, CKD is not
contributing to hypertension: according to the 2017 ACC/AHA
guideline, the lack of contribution of CKD to hypertension is at
least 15- to 35-fold more common than CKD contributing to hy-
pertension, with the fold-change range depending on age [2],
and according to the 2018 ESH/ESC guidelines, CKD not contrib-
uting to hypertension is at least 3- to 7-fold more common than
CKD contributing to hypertension [3].
WHY OLDER DEFINITIONS OF HYPERTENSIVE
NEPHROPATHY MAY BE OUTDATED
Hypertension and CKD are closely linked. Thus the diagnostic
conundrum in a hypertensive CKD patient is whether hyperten-
sion caused CKD or CKD caused hypertension. This latter
possibility would mean that hypertension is considered to be
secondary to CKD. A third possibility would be to consider both
entities coexistent and unrelated, and that, although theoreti-
cally possible, is unlikely. Reading the diagnostic criteria for hy-
pertensive nephrosclerosis, it becomes clear that the whole
field of the causal relationship between hypertension and CKD
must be rethought and that CKD is likely a more frequent cause
of hypertension than what is presented in guidelines or text-
books. Thus, for example, according to UpToDate,
the diagnosis of hypertensive nephrosclerosis is generally inferred
from the characteristic clinical features and the exclusion of other
kidney diseases. . .. Affected patients usually have a long history
of hypertension that is typically accompanied by left ventricular
hypertrophy, a relatively normal urine sediment, small kidneys,
and, if previous information is available, slowly progressive renal
insufficiency with gradually increasing proteinuria that is usually
nonnephrotic. . .. Most important from a clinical viewpoint, the
hypertension precedes the development of either proteinuria or
renal insufficiency, and there is no other obvious cause of renal
disease [10].
Reading this definition, one is confronted with the thought
that it is describing CKD of unknown cause. Thus, for two
patients with the same characteristics, if a cause of CKD is obvi-
ous, it would be called CKD-induced hypertension, but if the
cause is not obvious (i.e. CKD of unknown cause) then it is called
hypertensive nephrosclerosis, which would be most CKD
patients of whatever cause that have reached this stage in
which the kidneys are small. The fact that hypertension
‘precedes the development of either proteinuria or renal insuffi-
ciency’ does not mean that hypertension is causing either of
them, since pathological albuminuria is already diagnostic of
CKD and may precede overt proteinuria by decades and a diag-
nosis of renal insufficiency (eGFR <60 mL/min) means that CKD
has been progressing, also potentially over decades, leading to a
progressive decrease in GFR from 120 mL/min to <60 mL/min
[5, 11]. Thus CKD is currently diagnosed much earlier in the
course of kidney disease (e.g. when normal GFR is still normal
but albuminuria is already pathological, such as values persis-
tently 40 mg/g) than chronic kidney insufficiency was diag-
nosed in the 20th century (e.g. serum creatinine well above the
upper limit of the normal range, independent of muscle mass).
Thus it is not enough that hypertension precedes kidney insuf-
ficiency, it should also precede the earliest evidence of CKD to
start thinking about attributing CKD to hypertension and not
the other way around.
WHAT DID THE KDIGO CONTROVERSIES
CONFERENCE 2019 SAY?
The conclusions of a KDIGO Controversies Conference on Blood
Pressure in CKD were published in 2019 [12]. They were disap-
pointing. Basically the 2012 KDIGO Clinical Practice Guideline
for the Management of Blood Pressure in Chronic Kidney
Disease [1] should be revised, but there are many sources of un-
certainty and this will not be easy. Difficulties include establish-
ing conversion factors to translate a casual BP value into a
standardized BP value, the lack of adequately powered random-
ized controlled trials of BP control on clinical outcomes that
have targeted ambulatory or home BP in the CKD or general
adult population and how to translate the findings from the
Systolic Blood Pressure Intervention Trial into BP thresholds
and targets, which should be reconsidered. In this regard, the
choice of thresholds and targets for lower-risk populations will
inform the need to define higher-risk subpopulations that re-
quire different, more stringent targets. The key conclusion was
thus that the 2012 KDIGO BP guideline is outdated.
WHAT CAN BE DONE ABOUT IT?
The existence of multiple different definitions of CKD to label a
hypertensive patient as having CKD for therapeutic decision-
making purposes as well as the existence of multiple different
BP thresholds to initiate antihypertensive drug therapy and of
multiple targets for such therapy creates confusion as physi-
cians are exposed to different guidelines in manuscripts or
meetings. It is difficult to keep track of the subtleties regarding
the different definitions of CKD and thresholds and targets for
such populations. It is likely that the final result will be a mix-
up of guidelines: certain populations defined in one guideline
may be applied thresholds and targets meant for a different
‘CKD’ population by another guideline. This chaos may eventu-
ally promote therapeutic nihilism: if there are so many different
thresholds or targets supported by a careful review of the evi-
dence by experts, then any threshold or target may be correct or
maybe none of them are correct. A larger danger lies in patient
perceptions of the issue. Until recently, patients were content
with following physician advice. But now they access online in-
formation, including different guidelines. An interconnected
world means that patients have access, as do physicians, to the
online guidelines. They also may realize the discrepancies and
may become painfully aware of the chaotic situation. This may
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decrease their trust in the medical community or individual
doctors.
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